Figure 1


All patients receiving anti-VEGF treatment between 1st Jan 2008 and 31st Dec 2012
= 818 patients (927 eyes)
Excluded (n=208)
90 patients (107 eyes) received anti-VEGF for reasons other than nAMD or bevacizumab for any indication
79 patients (81 eyes) had less than 1 year follow up data available from date of first injection
38 patients treated privately
1 patient less than 50 years old
All patients aged 50 years and older receiving NHS treatment with ranibizumab for nAMD with at least 1 year follow up data available
= 610 patients (653 eyes)